Literature DB >> 25773232

A glass polyalkenoate cement carrier for bone morphogenetic proteins.

Adel M F Alhalawani1, Omar Rodriguez, Declan J Curran, Russell Co, Sean Kieran, Saad Arshad, Timothy J Keenan, Anthony W Wren, Gazelle Crasto, Sean A F Peel, Mark R Towler.   

Abstract

This work considers a glass polyalkenoate cement (GPC)-based carrier for the effective delivery of bone morphogenetic proteins (BMPs) at an implantation site. A 0.12 CaO-0.04 SrO-0.36 ZnO-0.48 SiO2 based glass and poly(acrylic acid) (PAA, Mw 213,000) were employed for the fabrication of the GPC. The media used for the water source in the GPC reaction was altered to produce a series of GPCs. The GPC liquid media was either 100 % distilled water with additions of albumin at 0, 2, 5 and 8 wt% of the glass content, 100 % formulation buffer (IFB), and 100 % BMP (150 µg rhBMP-2/ml IFB). Rheological properties, compressive strength, ion release profiles and BMP release were evaluated. Working times (Tw) of the formulated GPCs significantly increased with the addition of 2 % albumin and remained constant with further increases in albumin content or IFB solutions. Setting time (Ts) experienced an increase with 2 and 5 % albumin content, but a decrease with 8 % albumin. Changing the liquid source to IFB containing 5 % albumin had no significant effect on Ts compared to the 8 % albumin-containing BT101. Replacing the albumin with IFB/BMP-2 did not significantly affect Tw. However, Ts increased for the BT101_BMP-2 containing GPCs, compared to all other samples. The compressive strength evaluated 1 day post cement mixing was not affected significantly by the incorporation of BMPs, but the ion release did increase from the cements, particularly for Zn and Sr. The GPCs released BMP after the first day, which decreased in content during the following 6 days. This study has proven that BMPs can be immobilized into GPCs and may result in novel materials for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773232     DOI: 10.1007/s10856-015-5494-3

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  43 in total

Review 1.  Protein instability in poly(lactic-co-glycolic acid) microparticles.

Authors:  M van de Weert; W E Hennink; W Jiskoot
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

Review 2.  Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts).

Authors:  P C Bessa; M Casal; R L Reis
Journal:  J Tissue Eng Regen Med       Date:  2008-01       Impact factor: 3.963

Review 3.  Biomaterial delivery of morphogens to mimic the natural healing cascade in bone.

Authors:  Manav Mehta; Katharina Schmidt-Bleek; Georg N Duda; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2012-05-22       Impact factor: 15.470

4.  Reactions in glass ionomer cements: II. An infrared spectroscopic study.

Authors:  S Crisp; M A Pringuer; D Wardleworth; A D Wilson
Journal:  J Dent Res       Date:  1974 Nov-Dec       Impact factor: 6.116

5.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

6.  Restoration of segmental bone defects in rabbit radius by biodegradable capsules containing recombinant human bone morphogenetic protein-2.

Authors:  M Mori; M Isobe; Y Yamazaki; K Ishihara; N Nakabayashi
Journal:  J Biomed Mater Res       Date:  2000-05

7.  The processing, mechanical properties and bioactivity of strontium based glass polyalkenoate cements.

Authors:  Anthony Wren; Daniel Boyd; M R Towler
Journal:  J Mater Sci Mater Med       Date:  2007-10-18       Impact factor: 3.896

8.  Comparison of an experimental bone cement with surgical Simplex P, Spineplex and Cortoss.

Authors:  D Boyd; M R Towler; A Wren; O M Clarkin
Journal:  J Mater Sci Mater Med       Date:  2008-01-16       Impact factor: 3.896

9.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

Review 10.  Generation of microgrooved silica nanotube membranes with sustained drug delivery and cell contact guidance ability by using a Teflon microfluidic chip.

Authors:  Song Chen; Xuetao Shi; Shanmugavel Chinnathambi; Hongkai Wu; Nobutaka Hanagata
Journal:  Sci Technol Adv Mater       Date:  2013-02-13       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.